Probiotic Bacteria as Therapeutics and Biohybrid Drug Carriers: Advances, Design Strategies, and Future Outlook
ACS Applied Bio Materials · 2025
DOI: 10.1021/acsabm.5c00959 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ACS Applied Bio Materials, 2025. Verfasst von Deepsundar Sahoo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, University of Texas at Arlington, Arlington, Texas 76010, United States. Hauptthemen laut MEDLINE: Probiotics, Drug Carriers, Biocompatible Materials, Bacteria. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 193 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Probiotic bacteria have emerged as versatile and biocompatible platforms for drug delivery, offering a safe and efficient means of targeting diseased tissues. Advances in nanotechnology and genetic engineering have significantly expanded the potential of probiotic bacteria in precision medicine, enabling the delivery of therapeutics, proteins, antigens, and nanoparticles (NPs). This review explores diverse strategies for utilizing probiotics as drug carriers, including bacterial ghosts, outer membrane vesicles (OMVs), surface membrane proteins, and spores, focusing on applications in cancer therapy, vaccine development, and gastrointestinal disorders. We primarily focus on the strategy of integrating probiotics into nanoparticle-based delivery systems, examining key design considerations, such as functionalization strategies, targeting efficiency, and biocompatibility. Additionally, we highlight genetic engineering approaches, including plasmid-based expression and genomic integration, that enhance the probiotic functionality for targeted therapy, immunomodulation, and nanoparticle-mediated drug delivery. Further advancements in synthetic biology, biohybrid coatings, and stimulus-responsive mechanisms that could optimize the therapeutic efficacy of these systems will be discussed briefly. This review comprehensively analyzes recent progress and the outlook for harnessing probiotics for next-generation targeted drug delivery applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioengineering, University of Texas at Arlington, Arlington, Texas 76010, United States.
- Joint Bioengineering Program, University of Texas Southwestern Medical Center, Dallas, Texas 75235, United States.
ORCID-Profile: Uday Chintapula
Zitieren
APA
Sahoo, D., Rodriguez, E., Nguyen, K., & Chintapula, U. (2025). Probiotic Bacteria as Therapeutics and Biohybrid Drug Carriers: Advances, Design Strategies, and Future Outlook. ACS Applied Bio Materials. https://doi.org/10.1021/acsabm.5c00959
Vancouver
Sahoo D, Rodriguez E, Nguyen K, Chintapula U. Probiotic Bacteria as Therapeutics and Biohybrid Drug Carriers: Advances, Design Strategies, and Future Outlook. ACS Applied Bio Materials. 2025. doi:10.1021/acsabm.5c00959
BibTeX
@article{Sahoo2025,
author = {Sahoo, Deepsundar and Rodriguez, Edgar and Nguyen, Kytai and Chintapula, Uday},
title = {Probiotic Bacteria as Therapeutics and Biohybrid Drug Carriers: Advances, Design Strategies, and Future Outlook},
journal = {ACS Applied Bio Materials},
year = {2025},
doi = {10.1021/acsabm.5c00959}
}
EUVIMED